Use of Allied-health Professionals to Improve Treatment of Disease

NCT06337799 | Not Yet Recruiting

• 1 other identifier: 202210411
• Study Type: interventional
• Target: 200
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this clinical trial is to learn if allied-health professionals can recruit and follow research participants, sustain engagement, and improve and diagnose treatment of diseases by facilitating transitions of care. Participants will: Take their blood pressure at home and return it to the research team; Follow up with a research pharmacist for 12 months; Return for a follow up visit after 12 months.

Conditions

Preeclampsia

Outcome Measures

Primary Outcomes (6)

• Number of Subjects at Risk for Hypertension

  We will calculate the number of participants who are at risk for hypertension during the course of the intervention.

  Through study completion, an average of 12 months

• Number of Subjects Exposed to a Screening Clinic

  We will calculate the number of participants who visited a screening clinic during the course of the intervention.

  Through study completion, an average of 12 months

• Number of Subjects Screened at a Screening Clinic

  We will calculate the number of participants who were screened at a screening clinic during the intervention.

  Through study completion, an average of 12 months

• Number of Subjects Followed-Up by the Research Pharmacist

  We will calculated the number of participants who were followed-up by a research pharmacist during the intervention.

  Through study completion, an average of 12 months

• Number of Subjects Diagnosed with Hypertension

  We will calculate the number of participants who were diagnosed with hypertension by their provider during the intervention.

  Through study completion, an average of 12 months

• Number of Subjects Treated for Hypertension, if Diagnosed

  We will calculate the number of participants who were treated for their hypertension diagnosis by their provider, if they were diagnosed with hypertension, during the intervention.

  Through study completion, an average of 12 months

Study Arms (1)

Research Pharmacist Monitoring

EXPERIMENTAL

The research pharmacist will help the mother find a primary care physician if she doesn't have one and discuss strategies to lower blood pressure, if needed. The pharmacist interactions will occur 7 days after enrollment and then approximately every 2 weeks to 2 months during 12 months of follow up, depending on blood pressure control. They may recommend medications to the participant's physician. The pharmacist will have access to the participant's electronic medical record to obtain any blood pressure-related medications that the mother is prescribed as well as throughout the follow up to ensure any health-related conditions can be discussed.

Behavioral: Research Pharmacist

Interventions

Research Pharmacist BEHAVIORAL

The goal of this intervention is to determine if allied health professionals will improve blood pressure in new mothers.

Research Pharmacist Monitoring

Eligibility Criteria

• Age: 18 Years - 55 Years
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Biological mothers delivering at UIHC or attending a well-child visit for an infant between 1 month and 9 months
• Preeclampsia during pregnancy
• Preceived prenatal care at UIHC
• Owns a smartphone

You may not qualify if:

• Arm circumference greater than 17 inches
• Prisoner status
• Unable to provide own written informed consent

Sponsors & Collaborators

• University of Iowa: lead

MeSH Terms

Conditions

Pre-Eclampsia

Condition Hierarchy (Ancestors)

Hypertension, Pregnancy-Induced; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases

Study Officials

• Philip M Polgreen, MD

  University of Iowa

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Philip M Polgreen, MD

CONTACT

319-384-6194; philip-polgreen@uiowa.edu

Shelby L Francis, PhD

CONTACT

319-678-8037; shelby-francis@uiowa.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: March 22, 2024
• First Posted: March 29, 2024
• Study Start (Estimated): October 1, 2026
• Primary Completion (Estimated): March 1, 2030
• Study Completion (Estimated): March 1, 2030
• Last Updated: May 31, 2025

Record last verified: 2025-05